PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

Thumbnail

New Drug Application for PSMA-PET 'cold kit' could expand access to prostate imaging

If approved, the kit could allow for more flexible production of prostate cancer imaging agents.

alzheimer's disease dementia brain imaging

Machine learning winnows memory-care cohort to only the most appropriate nuc-med patients

An AI-aided way has emerged to confidently select dementia patients who are likely to benefit from amyloid-PET imaging while appropriately de-selecting patients for whom the costly exam would probably be unhelpful.  

medical imaging carbon emissions climate change

PET is an energy hog, but relatively rare utilization lessens its carbon footprint. MRI and CT have no such ‘out’

Medical imaging machinery uses a lot of power, and the extent to which it quickens the pace of global warming is becoming clearer.

A newly identified PET imaging biomarker could help providers tailor immunotherapy treatments for patients with certain types of cancers.

Researchers identify new PET imaging biomarker capable of predicting immunotherapy success

A newly identified PET imaging biomarker could help providers tailor immunotherapy treatments for patients with certain types of cancers. 

merger acquisition handshake deal business agreement partnership

Siemens Healthineers inks data sharing deal with Blue Earth to bolster development of prostate cancer AI

Blue Earth will be sharing anonymized clinical data from its Phase 3 Lighthouse trial involving the use of PET imaging agent Posluma.

Whole-body maximum-intensity projections over time after [68Ga]Ga-DPI-4452 administration.

New PET agent offers 'exceptional' imaging of kidney cancer

The agent was found to be better than standard CT imaging for patients with clear cell renal cell cancer.

Multiple sclerosis ribbon MS

New PET technique spots 'smoldering' changes not visible on MRI in the brains of MS patients

The new technique uncovers hidden inflammation in patients who, despite undergoing extensive treatment for the condition, had worsening symptoms.

Imaging agent that targets deadly brain tumors given FDA's Fast Track designation

Fast Track designations are typically granted to drugs that target an unmet medical need.